{
  "claim_id": "claim_000",
  "claim": "Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
  "document": "Hsiao_et_al.__2023_",
  "verification_stats": {
    "total_extracted": 1,
    "verified": 0,
    "rejected": 1,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": "comp_1",
      "quote": "BACKGROUND Quadrivalent recombinant influenza vaccines contain three times the amount of hemagglutinin protein as standard dose egg based vaccines, and the recombinant formulation is not susceptible to antigenic drift during manufacturing.",
      "reason": "does not support claim",
      "original_explanation": "This quote supports the claim by stating that the recombinant formulation (Flublok) is not susceptible to antigenic drift during manufacturing, which is a key reason it can ensure an identical antigenic match with the WHO- and FDA-selected flu strains."
    }
  ],
  "model_used": "gpt-4.1"
}